Showing results (31-40 of 62) with videos related to
Sort By:
Pageof 7
Leukemia & Lymphoma|May 2, 2013
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study GroupPaula Cramer, Anna-Maria Fink, Raymonde Busch, et al.Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.Blood|June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutationsPaula Cramer, Eugen Tausch, Julia von Tresckow, et al.Haematologica|August 29, 2015
Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)Paula Cramer, Susanne Isfort, Jasmin Bahlo, et al.American Journal of Hematology|June 22, 2019
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)Othman Al-Sawaf, Alexandra Bazeos, Sandra Robrecht, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2016
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study GroupGabor Kovacs, Sandra Robrecht, Anna Maria Fink, et al.Pharmaceutical Research|May 3, 2019
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS TrialSilvia Maria Lavezzi, Jan de Jong, Martine Neyens, et al.Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2011
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.Clinical Lymphoma, Myeloma & Leukemia|August 1, 2018
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell LymphomaSusan O'Brien, Peter Hillmen, Steven Coutre, et al.Pageof 7